OK Van what say you.
Lastly, for DEXTENZA for the treatment of occular itching associated with allergic conjunctivitis, we submitted an sNDA at the end of 2020 and have received a PDUFA target action date of October 18, 2021. Overall, we believe the data package highlights a compelling product profile targeting an unmet need that could potentially change the current standard of care with the physician-administered, preservative-free, hands-free therapy for these patients, which can't be abused by patients. As Antony mentioned, if approved, this sNDA would represent our first in-office indication for DEXTENZA.
Lastly, for DEXTENZA for the treatment of occular itching associated with allergic conjunctivitis, we submitted an sNDA at the end of 2020 and have received a PDUFA target action date of October 18, 2021. Overall, we believe the data package highlights a compelling product profile targeting an unmet need that could potentially change the current standard of care with the physician-administered, preservative-free, hands-free therapy for these patients, which can't be abused by patients. As Antony mentioned, if approved, this sNDA would represent our first in-office indication for DEXTENZA.
Last edited: